TRAJ58 Regulates T Cell Response and Immune Functions (G28697)

Target Name: TRAJ58

NCBI ID: G28697

TRAJ58

Other Name(s): T cell receptor alpha joining 58 (non-functional)

TRAJ58 Regulates T Cell Response and Immune Functions

T cell receptor alpha-joining 58 (TRAJ58), also known as non-functional T cell receptor alpha-joining 58, is a protein that plays a critical role in the regulation of T cell responses. Trajectin 58 is a non-functional T cell receptor alpha-joining protein which can interact with the protein PD-L1. This interaction between the two proteins is crucial in regulating the regulation of T cell responses, including the regulation of cell proliferation and differentiation.

TRAJ58 is a protein that is expressed in various tissues, including the spleen, lymph nodes, and Peyer's patches. It is a 120-kDa protein that is composed of two heavy chains and two light chains. The heavy chains contain four variable regions, including a single constant region and three variable regions. The variable regions contain the amino acids that are responsible for the interaction between TRAJ58 and PD-L1.

The function of TRAJ58 is to form the alpha-chain of the T cell receptor. The alpha-chain is the portion of the T cell receptor that interacts with the PD-L1 protein. The interaction between TRAJ58 and PD-L1 allows for the regulation of T cell responses, including the regulation of cell proliferation and differentiation.

TRAJ58 is regulated by several factors, including cytokines, chemokines, and intracellular signaling pathways. One of the well-known regulations of TRAJ58 is the interaction with PD-L1. PD-L1 is a protein that is expressed in various tissues, including the spleen, lymph nodes, and Peyer's patches. It is a 160-kDa protein that is composed of two heavy chains and two light chains. The heavy chains contain four variable regions, including a single constant region and three variable regions. The variable regions contain the amino acids that are responsible for the interaction between PD-L1 and TRAJ58.

The interaction between TRAJ58 and PD-L1 is critical in regulating the regulation of T cell responses. TRAJ58 can interact with PD-L1 through its variable regions, allowing for the regulation of T cell responses. One of the well-known functions of TRAJ58 is its role in the regulation of cell proliferation and differentiation. TRAJ58 can interact with PD-L1 and regulate the activity of the transcription factor PDX-1, which is responsible for the regulation of cell proliferation and differentiation.

Another function of TRAJ58 is its role in the regulation of immune responses. TRAJ58 can interact with PD-L1 and regulate the activity of the transcription factor NF-kappa-B, which is responsible for the regulation of immune responses. TRAJ58 can also interact with the protein PD-1 and regulate the activity of the T cell receptor, allowing for the regulation of T cell responses.

TRAJ58 is also regulated by several signaling pathways, including the PI3K/Akt signaling pathway. This signaling pathway is responsible for the regulation of cell proliferation and differentiation, and TRAJ58 is regulated by this pathway through its interaction with PD-L1.

In conclusion, T cell receptor alpha-joining 58 (TRAJ58) is a non-functional T cell receptor alpha-joining protein that plays a critical role in the regulation of T cell responses. The interaction between TRAJ58 and PD-L1 is crucial in regulating the regulation of T cell responses, including the regulation of cell proliferation and differentiation, and the regulation of immune responses. Therefore, TRAJ58 is a potential drug target and a biomarker for the treatment of various diseases, including cancer, autoimmune diseases, and neurodegenerative diseases.

Protein Name: T Cell Receptor Alpha Joining 58 (non-functional)

The "TRAJ58 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAJ58 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets